Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes

Abstract

Amphotericin B deoxycholate (AmBd) has been a standard therapy for IFI but is associated with high adverse event and mortality rates. A retrospective review was undertaken to describe adverse events and clinical outcomes in adult patients with IFI treated with only AmBd as initial therapy.